- NORTH AMERICA EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Canntab Therapeutics was recently featured in an article by the Financial Post. The article discusses the company’s seven filed patent applications for two types of cannabis tablets.
Canntab Therapeutics was recently featured in an article by the Financial Post. The article discusses the company’s seven filed patent applications for two types of cannabis tablets.
As quoted in the article,
Canntab, whose motto is putting the medical into medicinal cannabis, is a different sort of medical marijuana related company. Its business is producing tablets, which would give medical marijuana users a different way of ingesting cannabis. (Hence the stock symbol: PILL.)
“We are the first in Canada, and possibly in the rest of the world,” said Richard Goldstein, the company’s chief financial officer, who formed Canntab with chief executive Jeff Renwick in the middle of 2016.
Other plans for the company include expanding into certain U.S. states, where they will “be seeking a manufacturing and distributors licence.”
Click here to read the full article.
Click here to connect with Canntab Therapeutics
Source: business.financialpost.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.